CD38 and hyperinsulinemic hypoglycemia, familial, 4: Moreover, in the realm of immunotherapy, there are clues suggesting that the combination of ICB therapy with anti-CD38/anti-CD74 complexes or ICB therapy combined with CCR5 inhibitors may ameliorate the immune suppression caused by BAP1 deficiency [12, 32], while these strategies have not yet entered the clinical trial stage.